Meta (META) stock is dipping on reports that the company is restructuring its artificial intelligence (AI) unit for the ...

Novo Nordisk cuts prices. In a pair of press releases this morning, Novo announced it's cutting the cash cost for 0.5 mg, 1 ...

Insider trading activity often serves as a window into how company executives view their own businesses. When insiders buy, ...

Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required ...

Novo Nordisk shares (DK:NOVO.B) (NVO) rose 5% in opening New York trade. The American depository receipts however have plunged 37% this year amid increased competition for its weight-loss drugs as ...

Ozempic accidentally became a cultural phenomenon. The drug, first delivered to diabetes patients in 2017, had a huge impact ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

Investing.com -- GoodRx (NASDAQ: GDRX) stock surged 18% after announcing a collaboration with Novo Nordisk (NYSE: NVO) to offer Ozempic and Wegovy to eligible self-paying patients for $499 per month.

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.

Eli Lilly & Novo Nordisk target cash-pay customers in the GLP-1 weight loss market with $499 monthly offers. Read more here.

Novo Nordisk A/S innovation and growth continue to shine. Now, it has a partnership with GoodRX Holdings. Click for my ...